Briacell Therapeutics Corp.
SEC CIK 1610820 · BCTX · last insider filing 2024-05-20
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Lustig Marc | Director | filed 2022 - 2024 |
| Williams Williams V. | Director · President, CEO | filed 2022 - 2022 |
| Bondarenko Jamieson | Director · Chairman | filed 2022 - 2022 |
| Taub Rebecca | Director | filed 2022 - 2022 |
| Gross Jane A | Director | filed 2022 - 2022 |
| Schmieg Martin E. | Director | filed 2022 - 2022 |
| Embro-Pantalony Vaughn C. | Director | filed 2022 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Del Priore Giuseppe | Chief Medical Officer | filed 2022 - 2022 |
| Levin Gadi | CFO & Secretary | filed 2022 - 2022 |
| Lopez-Lago Miguel A. | Chief Scientific Officer | filed 2022 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.